2591’s safety profile is very good, and with the indications we are targeting I believe you only need to show moderate improvements in the efficacy for the FDA to approve. As long as its safe to use.
Ann: Completion of enrolment in Neuren's Angelman P2 trial, page-46
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
0.070(0.35%) |
Mkt cap ! $2.578B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $4.102M | 202.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 249 | $20.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.31 | 790 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |